156 related articles for article (PubMed ID: 38668044)
1. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar P; Geirnaert M; Gavura S; Beca J; Mercer RE; Denburg A; Muñoz C; Tadrous M; Parmar A; Dionne F; Boehm D; Chambers C; Craig E; Trudeau M; Cheung MC; Houlihan J; McDonald V; Pechlivanoglou P; Taylor M; Wasylenko E; Wranik WD; Chan KKW
Curr Oncol; 2024 Apr; 31(4):1876-1898. PubMed ID: 38668044
[TBL] [Abstract][Full Text] [Related]
2. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Parmar A; Dai WF; Dionne F; Geirnaert M; Denburg A; Ahuja T; Beca J; Bouchard S; Chambers C; Hunt MJ; Husereau D; Lungu E; McDonald V; Mercer RE; Mitera G; Muñoz C; Naipaul R; Peacock S; Potashnik T; Tadrous M; Takhar P; Taylor M; Trudeau M; Wasney D; Gavura S; Chan KKW
Curr Oncol; 2023 Mar; 30(4):3776-3786. PubMed ID: 37185399
[TBL] [Abstract][Full Text] [Related]
3. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
[TBL] [Abstract][Full Text] [Related]
4. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
5. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Dai WF; Craig E; Fraser B; Chambers A; Mai H; Brown MB; Earle CC; Evans WK; Geirnaert M; Taylor M; Trudeau M; Sperber D; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
Curr Oncol; 2021 Nov; 28(6):4645-4654. PubMed ID: 34898572
[TBL] [Abstract][Full Text] [Related]
6. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF; Arciero V; Craig E; Fraser B; Arias J; Boehm D; Bosnic N; Caetano P; Chambers C; Jones B; Lungu E; Mitera G; Potashnik T; Reiman A; Ritcher T; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group
Curr Oncol; 2021 Oct; 28(5):4174-4183. PubMed ID: 34677272
[TBL] [Abstract][Full Text] [Related]
7. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
8. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
[TBL] [Abstract][Full Text] [Related]
9. Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned.
Evans WK; Takhar P; McDonald V; Elias M; Binder L; Michaud S; Tadrous M; Muñoz C; Chan KKW
Curr Oncol; 2022 Aug; 29(8):5616-5626. PubMed ID: 36005181
[TBL] [Abstract][Full Text] [Related]
10. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
[TBL] [Abstract][Full Text] [Related]
11. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
[TBL] [Abstract][Full Text] [Related]
12. Ranking Decision-Making Criteria for Early Adoption of Innovative Surgical Technologies.
Shoman H; Almeida ND; Tanzer M
JAMA Netw Open; 2023 Nov; 6(11):e2343703. PubMed ID: 37971741
[TBL] [Abstract][Full Text] [Related]
13. Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework.
Campolina AG; Estevez-Diz MDP; Abe JM; de Soárez PC
PLoS One; 2022; 17(5):e0268584. PubMed ID: 35613115
[TBL] [Abstract][Full Text] [Related]
14. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
[TBL] [Abstract][Full Text] [Related]
15. A Rapid Literature Review of Multi-Criteria Decision Support Methods in the Context of One Health for All-Hazards Threat Prioritization.
Zhao J; Smith T; Lavigne M; Aenishaenslin C; Cox R; Fazil A; Johnson A; Sanchez J; Hermant B
Front Public Health; 2022; 10():861594. PubMed ID: 35493347
[TBL] [Abstract][Full Text] [Related]
16. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
[TBL] [Abstract][Full Text] [Related]
17. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
Angelis A; Montibeller G; Hochhauser D; Kanavos P
BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
[TBL] [Abstract][Full Text] [Related]
18. Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience.
Laba TL; Jiwani B; Crossland R; Mitton C
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32762789
[TBL] [Abstract][Full Text] [Related]
19. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
Diaby V; Goeree R; Hoch J; Siebert U
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):13-9. PubMed ID: 25267699
[TBL] [Abstract][Full Text] [Related]
20. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
